Advertisement
Advertisement

EU backs use of Novo Nordisk’s weight loss drug in adolescents

By:
Reuters
Published: Mar 31, 2023, 15:30 GMT+00:00

(Reuters) -The European Medicines Agency said on Friday its committee has recommended expanding the use of Danish drugmaker Novo Nordisk's weight loss drug in adolescents aged 12 years and older.

The logo of Danish multinational pharmaceutical company Novo Nordisk is pictured on the facade of a production plant in Chartres

(Reuters) -The European Medicines Agency said on Friday its committee has recommended expanding the use of Danish drugmaker Novo Nordisk’s weight loss drug in adolescents aged 12 years and older.

The drugmaker told Reuters the Committee for Medicinal Products for Human Use’s (CHMP) positive opinion was an “important recognition of the unmet medical need among adolescents living with obesity and the need for additional treatment options”.

Novo’s Wegovy, a semaglutide-based drug, activates GLP-1, a hormone that triggers the feeling of fullness in the body after eating. It has been approved in the U.S. and European Union for treatment of obesity in adults.

The company did not indicate a timeline for its plans to launch the drug, already available in Denmark and Norway, in other EU countries.

Earlier this year, the American Academy of Pediatrics also recommended use of weight-loss drugs in children aged 12 years or older, following the U.S. Food and Drug Administration’s approval in December of the drug for that population.

(Reporting by Radhika Anilkumar and Bhanvi Satija in Bengaluru and Nikolaj Skydsgaard in Copenhagen; Editing by Shinjini Ganguli, Kirsten Donovan)

About the Author

Reuterscontributor

Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV. Learn more about Thomson Reuters products:

Did you find this article useful?

Advertisement